Modafinil (Provigil)

A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.

Also Known As:

Provigil; Alertec; Modiodal; Nuvigil; 2-((Diphenylmethyl)sulfinyl)acetamide; 2-((R)-(Diphenylmethyl)sulfinyl)acetamide; Armodafinil; Benzhydrylsulfinylacetamide; CRL 40476; CRL-40476; R-Modafinil; Sparlon; 2 Benzhydrylsulfinylacetamide; R Modafinil; 2-(Benzhydrylsulfinyl)acetamide; 2-Benzhydrylsulfinylacetamide

Networked: 1105 relevant articles (270 outcomes, 329 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzhydryl Compounds
        Modafinil: 1105

Experts

1.	Yang, Ronghua: 21 articles (12/2015 - 01/2006)
2.	Dauvilliers, Yves: 17 articles (12/2021 - 01/2003)
3.	Roth, Thomas: 15 articles (12/2017 - 08/2005)
4.	Tufik, Sergio: 13 articles (07/2018 - 02/2008)
5.	Sahakian, Barbara J: 13 articles (03/2017 - 01/2003)
6.	Schwartz, Jonathan R L: 13 articles (10/2010 - 01/2003)
7.	Nishino, Seiji: 11 articles (11/2016 - 07/2006)
8.	Arora, Sanjay: 11 articles (12/2009 - 08/2005)
9.	Frye, Mark A: 9 articles (01/2020 - 08/2007)
10.	Darwish, Mona: 9 articles (11/2015 - 01/2006)

Related Diseases

1.	Fatigue 04/13/2016 - "Although this study found a significant improvement over time in the primary outcome of fatigue, the improvement occurred after both modafinil and placebo with no significant difference in response between the two groups. " 01/01/2017 - "Participants receiving modafinil reported a significant decrease in fatigue (multidimensional fatigue inventory, -7.38; 95% CI, -21.76 to -2.99; P<0.001) and improved quality of life (SSQoL, 11.81; 95% CI, 2.31 to 21.31; P=0.0148) compared with placebo. " 10/01/2015 - "While there was no overall significant effect on fatigue, those with greater baseline fatigue experienced improved QOL and reduced fatigue when using armodafinil. " 09/01/2012 - "After correcting for multiple comparisons of the 8 neuropsychological dependent measures, we found that the patients had significantly improved delayed memory on a list-learning task after they took armodafinil (P = 0.0005), but no improvement on measures of executive function, visual memory, processing speed, or self-reported fatigue. " 07/15/2010 - "ANCOVA showed a significant interaction between treatment condition and baseline fatigue (P=.017), where patients with severe baseline fatigue (n=458) benefited from modafinil, whereas patients with mild or moderate fatigue did not. "
2.	Sleepiness 01/01/2021 - "Modafinil significantly improved self-reported sleepiness on the Epworth Sleepiness Scale by 5.08 points more than placebo (95% confidence interval (CI) 3.01 to 7.16; 2 studies, 101 participants; high-certainty evidence). " 01/01/2016 - "Meta-analysis of the three trials evaluating modafinil showed a significant reduction in sleepiness, as assessed by the Epworth Sleepiness Scale (ESS) (- 2.24 points, 95% CI - 3.90 to - 0.57, p < 0.05). " 01/01/2017 - "Armodafinil led to statistically significant improvement in sleepiness compared to placebo as indicated by the ESS (the primary outcome; p < .002) as well as the Clinical Global Impression of Improvement in Sleepiness scale (key secondary outcome; p = .01). " 02/01/2015 - "Compared to placebo, modafinil decreased sleepiness significantly and improved mean sleep latency in the MWT non-significantly. " 11/15/2014 - "Armodafinil 250 mg significantly improved sleep latency in patients with excessive sleepiness associated with mild or moderate TBI. "
3.	Narcolepsy 10/01/2011 - "Because of its high safety and low side-effect profiles, modafinil has become the first-line treatment of choice for EDS associated with narcolepsy. " 09/01/2009 - "Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250 mg once daily in patients with OSA or narcolepsy, and with armodafinil 150 mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT). " 01/15/2007 - "In conclusion, modafinil did not influence thymopsychic variables in narcolepsy, but it significantly improved cognitive performance, which may be related to medial prefrontal activity processes identified by LORETA." 04/01/2006 - "Armodafinil significantly improved ability to sustain wakefulness throughout the day in patients with narcolepsy. " 07/01/2000 - ": Modafinil is effective for the long-term treatment of EDS associated with narcolepsy and significantly improves perceptions of general health. "
4.	Disorders of Excessive Somnolence (Hypersomnia) 04/01/1998 - "The efficacy of modafinil 200 or 400 mg/day was rated as good or excellent (using a 4-point scale) in 84 of 131 evaluable patients (64%) with excessive daytime sleepiness treated for 1 to 114 months in a noncomparative study. " 12/01/2007 - "However, the hypersomnia items on the 31-item Hamilton Depression Scale were significantly more improved with modafinil than placebo. " 12/01/2003 - "The addition of the selective psychostimulant modafinil resulted in significant improvement in the hypersomnia, with improvement in functioning. " 03/01/2003 - "Our data demonstrate that, in a small sample size, administration of 200 mg/day of modafinil was associated with few side effects and was modestly effective for the treatment of excessive daytime sleepiness in patients with PD." 08/01/1997 - "As little as a 200-mg daily dose of modafinil is therefore an effective and well-tolerated treatment of excessive daytime somnolence in narcoleptic persons."
5.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 08/15/2009 - "The results of this study indicate that modafinil significantly improved symptoms of ADHD, was well tolerated, and may open a new window in the treatment of children with ADHD." 01/01/2008 - "The results of this study indicate that modafinil significantly improved symptoms of ADHD and was well tolerated and it is beneficial in the treatment of children with ADHD." 01/01/2017 - "The results showed that modafinil more significantly improved ADHD-RS-IV Home (SMD, -0.77 [95%CI, -1.11 to -0.44]) and School (SMD, -0.71 [95%CI, -0.96 to -0.47]) than placebo. " 03/01/2008 - "Modafinil (vs placebo) significantly improved mean total scores for the ADHD-RS-IV School and Home Versions for the inattentive (change from baseline: School, modafinil, -15.7, placebo, -7.1; Home, modafinil, -13.8, placebo, -5.9) and combined subtypes (School, -16.5 vs -8.8; Home, -15.7 vs -7.6). " 05/01/2006 - "Modafinil significantly improved ADHD symptoms in children. "

Related Drugs and Biologics

1.	Modafinil (Provigil)
2.	Methylphenidate (Ritalin)
3.	Sodium Oxybate (gamma Hydroxybutyrate)
4.	Amantadine (Aman)
5.	Antidepressive Agents (Antidepressants)
6.	Wakefulness-Promoting Agents
7.	Dextroamphetamine (Dexedrine)
8.	Amphetamine (Amfetamine)
9.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
10.	Caffeine (No Doz)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Drug Therapy (Chemotherapy)
4.	Palliative Care (Palliative Therapy)
5.	Cognitive Training